序列特定的双重DNA结合模式和N-6功能化的诺克里普托塔基因类化合物的细胞毒性
Bhim Majhi1,2, Sudakshina Ganguly3, Subhadeep Palit1
1Organic and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, Kolkata 700032, India.
Journal of natural products
|June 7, 2023
概括
修改一种印罗基诺林类化物诺克里普托塔基因,降低了其DNA结合和细胞毒性. 通过改变DNA相互作用机制,N-6替代类型显示出治疗开发的潜力.
科学领域:
- 自然产品 化学 化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 诺克里普托塔基因是来自Cryptolepis sanguinolenta的印罗基诺林化物,传统上用于疟疾.
- 由于DNA结合诱导的细胞毒性,现有的印罗基诺林的临床应用有限.
- 结构性修改可以增强治疗潜力并降低毒性.
研究的目的:
- 为了研究N-6位置换对norcryptotackieine细胞毒性的影响.
- 探索有关特定序列DNA结合亲和性的结构-活性关系.
- 为了阐明N-6替代性或cryptotackieines的DNA结合机制.
主要方法:
- 合成N-6替代的诺克里普托塔基因类型 (6c, 6d).
- 在各种人类和小鼠细胞系中对细胞毒性的评估 (HEK293,OVCAR3,SKOV3,B16F10,HeLa).
- 对DNA结合的研究,以确定结合模式和序列选择性.
主要成果:
- 化合物6d表现出非间接性/伪间接性DNA结合,具有序列选择性.
- 与原始化合物相比,N-6替代改变了DNA结合机制.
- 在OVCAR3细胞中,Norcryptotackieine 6d的有效性比cryptolepine (IC50 1.64 μM) 低2倍 (IC50 3.1 μM). 在OVCAR3细胞中,Norcryptotackieine 6d的有效性比cryptolepine (IC50 1.64 μM) 低2倍.
结论:
- 诺克密托塔基因的N-6替代调节其DNA相互作用和细胞毒性.
- 这项研究确定了N-6替代的印罗基诺林的DNA结合机制.
- 这些发现为开发更安全,更有效的基于印罗基诺林的疗法提供了基础.
更多相关视频
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
9.6K
10:05Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin
Published on: January 20, 2016
8.3K
相关概念视频
Drug-Receptor Bonds
3.0K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
3.0K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Tissue-Drug Binding: Localization of Drugs and its Significance
115
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
115
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
